^
Association details:
| Biomarker: | EGFR L858R + EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations
Published date:
08/08/2023
Excerpt:
10 patients were retrospectively analyzed (median age,55 years; EGFR exon 19 deletion/21 L858R, 80%/20%; stages IIIA/IIIB/IIIC/IVA, 30%/20%/20%/30%)…Our study found that neoadjuvant aumolertinib for 8-14 weeks achieved much higher ORR (100% vs. 41.1-71%), pCR rate (25% vs. 0-12.1%), and MPR rate (87.5% vs. 11-70%) than historical data from other EGFR-TKIs...Neoadjuvant and adjuvant aumolertinib showed satisfying efficacy with excellent safety profile in stage IIIA-IVA unrecectable NSCLC. This is the first report that neoadjuvant aumolertinib has promising efficacy in stage IVA unrecectable NSCLC. Notably, all patients, including three with stage IVA, achieved conversion from unresectable to resectable status.
